Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07652697 · ClinicalTrials.gov registry record · Phase 1
ABX-002 Bioequivalence and Effect of Food Study in Healthy Adult Participants
A Phase 1 study, sponsored by Autobahn Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT07652697 is a Phase 1 study that has completed, run by Autobahn Therapeutics. The registered enrollment target is 18 participants.
The verdict
NCT07652697, a Phase 1 study, has completed, sponsored by Autobahn Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The goal of this study is to assess the bioequivalence (BE) between the liquid formulation and the new solid formulation of ABX-002 under fasting conditions and to evaluate the effect of food on the pharmacokinetics (PK) of the new solid formulation of ABX-002.This study design is consistent with FDA guidelines for the assessment of BE. This was an open label, randomized, single dose, three-way crossover BE and food-effect study. Therefore, the total number of participants in this study was 18.
Interventions
- DRUG ABX-002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-01-02 |
| Est. Completion | 2025-02-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07652697
The ClinicalTrials.gov registry entry for NCT07652697 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Autobahn Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABX-002 is the first listed.
NCT07652697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07652697 about?
NCT07652697 is a clinical study titled "ABX-002 Bioequivalence and Effect of Food Study in Healthy Adult Participants". The goal of this study is to assess the bioequivalence (BE) between the liquid formulation and the new solid formulation of ABX-002 under fasting conditions and to evaluate the effect of food on the pharmacokinetics (PK) of the new solid formulation of ABX-002.This study design is consistent with FD...
What is the current status of trial NCT07652697?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2025-01-02. Estimated completion is 2025-02-17.
What interventions are being tested in trial NCT07652697?
The interventions under investigation include: ABX-002 (DRUG).
Who is sponsoring clinical trial NCT07652697?
This trial is sponsored by Autobahn Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.